SAN

76.26

-1.73%↓

UCB

250.1

-3.1%↓

SHL.DE

40.38

-0.02%↓

ARGX

620.4

-1.02%↓

PHIA

24.97

-2.19%↓

SAN

76.26

-1.73%↓

UCB

250.1

-3.1%↓

SHL.DE

40.38

-0.02%↓

ARGX

620.4

-1.02%↓

PHIA

24.97

-2.19%↓

SAN

76.26

-1.73%↓

UCB

250.1

-3.1%↓

SHL.DE

40.38

-0.02%↓

ARGX

620.4

-1.02%↓

PHIA

24.97

-2.19%↓

SAN

76.26

-1.73%↓

UCB

250.1

-3.1%↓

SHL.DE

40.38

-0.02%↓

ARGX

620.4

-1.02%↓

PHIA

24.97

-2.19%↓

SAN

76.26

-1.73%↓

UCB

250.1

-3.1%↓

SHL.DE

40.38

-0.02%↓

ARGX

620.4

-1.02%↓

PHIA

24.97

-2.19%↓

Home・Akciju saraksts・Innate Pharma SA

I
Innate Pharma SA

Slēgts

1.344 -0.44

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.328

Max

1.374

Galvenie mērījumi
By Trading Economics
Ienākumi	-21M
Pārdošana	4.9M
EPS	-0.12
Peļņas marža	-439.177
Darbinieki	174
EBITDA	-25M

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 26. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	135M
Iepriekšējā atvēršanas cena	1.78
Iepriekšējā slēgšanas cena	1.344

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

1.91 / 2.1 Atbalsts un pretestība

Innate Pharma SA Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 6. marts 19:32 UTC

Iegādes, apvienošanās, pārņemšana

Diana Shipping Increases Offer to Acquire Genco -- Update

2026. g. 6. marts 17:44 UTC

Iegādes, apvienošanās, pārņemšana

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

2026. g. 6. marts 22:26 UTC

Galvenie ziņu notikumi

Why $100 Oil Is Now in Sight. Who Wins, Who Loses. -- Barrons.com

2026. g. 6. marts 22:07 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Boeing Says Spirit Acquisition Will Help Improve Safety -- Market Talk

2026. g. 6. marts 22:03 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 6. marts 22:03 UTC

Tirgus saruna

Boeing CEO's Pay Nears $24 Million During Recovery Phase -- Market Talk

2026. g. 6. marts 21:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Financial Services Roundup: Market Talk

2026. g. 6. marts 21:37 UTC

Peļņas

Salesforce Stock Might Not Be an AI Loser After All -- Barrons.com

2026. g. 6. marts 21:25 UTC

Galvenie ziņu notikumi

How The Iran War Impacts Ukraine. -- Barrons.com

2026. g. 6. marts 21:17 UTC

Peļņas

Burlington Stores' Strong Year Should Lift the Stock. What Comes Next. -- Barrons.com

2026. g. 6. marts 20:50 UTC

Peļņas

Marvell Stock Pops 20%. Semiconductor Earnings Show AI Demand Is Strong. -- Barrons.com

2026. g. 6. marts 20:46 UTC

Peļņas

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

2026. g. 6. marts 20:31 UTC

Galvenie ziņu notikumi

Oil Prices Soar Past $90. Trump Demands 'Unconditional Surrender' From Iran -- and Kuwait Cut Production. -- Barrons.com

2026. g. 6. marts 20:18 UTC

Tirgus saruna

Oil Makes Record Weekly Gains As Strait of Hormuz Stays Shut -- Market Talk

2026. g. 6. marts 20:12 UTC

Tirgus saruna

Galvenie ziņu notikumi

U.S. Natural Gas Futures Gain on Global Energy Turmoil -- Market Talk

2026. g. 6. marts 19:10 UTC

Tirgus saruna

Galvenie ziņu notikumi

$150 Oil Seen As Realistic If Hormuz Closure Lasts -- Market Talk

2026. g. 6. marts 18:54 UTC

Tirgus saruna

Fed's Hammack: Dollar Hasn't Lost Prime Status -- Market Talk

2026. g. 6. marts 18:44 UTC

Tirgus saruna

Galvenie ziņu notikumi

U.S. Oil Rig Count Increases By 4 to 411 -- Market Talk

2026. g. 6. marts 18:08 UTC

Peļņas

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

2026. g. 6. marts 18:04 UTC

Peļņas

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

2026. g. 6. marts 18:04 UTC

Peļņas

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

2026. g. 6. marts 17:49 UTC

Tirgus saruna

AI-Driven Picks-And-Shovels Bet Comes With Risks -- Market Talk

2026. g. 6. marts 17:46 UTC

Galvenie ziņu notikumi

Kuwait Cuts Oil Production as Fallout From Iran Conflict Intensifies -- Update

2026. g. 6. marts 17:40 UTC

Tirgus saruna

Peļņas

Marvell's Long-Term Outlook Well-Received By Investors -- Market Talk

2026. g. 6. marts 17:40 UTC

Peļņas

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

2026. g. 6. marts 17:32 UTC

Tirgus saruna

Galvenie ziņu notikumi

No Quick Solution for Hormuz Shipping as U.S. Oil Tops $90 -- Market Talk

2026. g. 6. marts 17:28 UTC

Tirgus saruna

Galvenie ziņu notikumi

Aluminum Rising as Strait of Hormuz Stays Locked -- Market Talk

2026. g. 6. marts 17:20 UTC

Tirgus saruna

Peļņas

Auto & Transport Roundup: Market Talk

2026. g. 6. marts 17:20 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 6. marts 17:20 UTC

Iegādes, apvienošanās, pārņemšana

BlackRock Sticks to Redemption Minimum on Credit Fund, Sends Shares Lower -- WSJ

Salīdzinājums

Cenas izmaiņa

Innate Pharma SA Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Innate Pharma SA — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

1.91 / 2.1Atbalsts un pretestība

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Innate Pharma SA

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.